Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $217.68M by Medicaid between Jan 2018 and Dec 2024, across 765 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BRONX, NY 10461
BRONX, NY 10461
33aNPI1679587679assigned 07/28/2006
33bProvider typeInternal Medicine Physician
28Total paid$217.68M
24GClaims4,737,613
24DCodes billed765
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#1 of 6,049
Median peer was paid$11K
This provider vs. median19,242×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,290 | $931K | |
| 2019 | 227,691 | $11.99M | |
| 2020 | 553,115 | $38.51M | |
| 2021 | 1,187,887 | $46.39M | |
| 2022 | 1,126,609 | $49.32M | |
| 2023 | 790,004 | $35.14M | |
| 2024incomplete | 774,017 | $35.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 129,725 | 121,268 | $24.40M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.0% | 181,474 | 158,289 | $15.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 77,522 | 72,182 | $13.96M |
| G9005 | Coordinated care fee, risk adjusted maintenance | 6.2% | 43,613 | 43,554 | $13.50M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.8% | 92,573 | 83,928 | $10.38M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 37,200 | 35,309 | $7.65M |
| T1016 | Case management, each 15 minutes | 3.5% | 31,288 | 31,288 | $7.59M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 3.1% | 13,718 | 12,136 | $6.80M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.4% | 90,745 | 81,605 | $5.15M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 57,015 | 50,871 | $3.78M |
| T1030 | Nursing care, in the home, by registered nurse, per diem | 1.4% | 28,628 | 9,131 | $3.14M |
| 81408 | 1.2% | 2,149 | 2,128 | $2.71M |
753 more codes
| 36415 | Collection of venous blood by venipuncture | 1.2% | 274,901 | $2.56M |
| 99204 | Doctor's office visit, new patient (more involved) | 1.1% | 14,974 | $2.47M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.1% | 14,236 | $2.31M |
| 90832 | Psychotherapy session, about 30 minutes | 1.0% | 15,957 | $2.22M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 39,479 | $2.14M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 17,687 | $2.13M |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 11,805 | $2.13M |
| 99285 | Emergency room visit (most serious) | <1% | 10,276 | $1.74M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 19,225 | $1.74M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,411 | $1.67M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,495 | $1.52M |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 2,185 | $1.51M |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 10,930 | $1.50M |
| S9123 | Nursing care, in the home; by registered nurse, per hour (use for general nursing care only, not to be used when cpt codes 99500-99602 can be used) | <1% | 10,382 | $1.39M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 81,273 | $1.34M |
| 99442 | <1% | 23,128 | $1.31M | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,552 | $1.30M |
| 80053 | Comprehensive metabolic panel | <1% | 122,705 | $1.30M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 47,862 | $1.30M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 37,775 | $1.27M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 10,877 | $1.21M |
| S9131 | Physical therapy; in the home, per diem | <1% | 11,659 | $1.11M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,800 | $1.11M |
| 99443 | <1% | 12,739 | $1.10M | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 937 | $964K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 7,501 | $942K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 40,019 | $920K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,190 | $888K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 68,447 | $881K |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 5,431 | $868K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 16,711 | $850K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 13,837 | $840K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 14,819 | $811K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,243 | $800K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 7,766 | $765K |
| 86480 | <1% | 12,579 | $760K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,041 | $741K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 879 | $736K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 22,463 | $718K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 9,170 | $704K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 8,537 | $697K |
| 99205 | Prolong outpt/office vis | <1% | 3,475 | $674K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,922 | $670K |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 662 | $669K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,381 | $661K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 7,216 | $653K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 25,708 | $651K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,771 | $649K |
| T1001 | Nursing assessment / evaluation | <1% | 5,991 | $633K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,855 | $597K |
| 85027 | <1% | 166,766 | $595K | |
| 86850 | <1% | 34,012 | $592K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 32,590 | $569K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,430 | $535K |
| 80061 | Lipid panel | <1% | 47,399 | $527K |
| 86703 | <1% | 37,035 | $522K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,016 | $503K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29,804 | $494K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,654 | $485K |
| G9001 | Coordinated care fee, initial rate | <1% | 6,455 | $482K |
| 90461 | <1% | 31,054 | $476K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 60,084 | $475K |
| 99441 | <1% | 14,316 | $457K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,081 | $456K |
| 76830 | Ultrasound, transvaginal | <1% | 6,176 | $455K |
| 86360 | <1% | 9,292 | $454K | |
| 97802 | <1% | 8,823 | $444K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 709 | $441K |
| 12001 | <1% | 1,949 | $438K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 62,176 | $430K |
| 81161 | <1% | 2,195 | $426K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 38,627 | $423K |
| H0040 | Assertive community treatment program, per diem | <1% | 345 | $408K |
| 12011 | <1% | 1,776 | $400K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 41,307 | $391K |
| 0002A | <1% | 14,412 | $391K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,517 | $390K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 18,029 | $384K |
| 87535 | <1% | 10,667 | $384K | |
| 86901 | <1% | 34,698 | $377K | |
| 76770 | <1% | 2,153 | $373K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 4,693 | $370K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 6,270 | $369K |
| 86359 | <1% | 9,269 | $362K | |
| 0001A | <1% | 14,573 | $361K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,608 | $361K |
| 90651 | <1% | 5,953 | $356K | |
| 93970 | <1% | 1,457 | $345K | |
| S9127 | Social work visit, in the home, per diem | <1% | 2,415 | $343K |
| 90715 | <1% | 13,913 | $340K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,896 | $339K |
| 76818 | <1% | 3,155 | $329K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,762 | $327K |
| 90677 | <1% | 3,872 | $327K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,208 | $315K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,824 | $307K |
| 83655 | <1% | 27,823 | $306K | |
| 86900 | <1% | 34,625 | $298K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,147 | $295K |
| 81329 | <1% | 2,394 | $286K | |
| 76801 | <1% | 2,297 | $281K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,133 | $275K |
| 86780 | <1% | 29,901 | $273K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,707 | $272K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,284 | $271K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 7,557 | $257K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,998 | $255K |
| 90686 | <1% | 24,961 | $245K | |
| 86803 | <1% | 23,673 | $244K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 2,745 | $240K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24,865 | $239K |
| 76813 | <1% | 2,279 | $238K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,922 | $237K |
| 87800 | <1% | 8,690 | $233K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 19,899 | $230K |
| 70486 | <1% | 1,820 | $228K | |
| 12002 | <1% | 1,026 | $220K | |
| 71250 | <1% | 1,119 | $213K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,796 | $211K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 378 | $204K |
| 90750 | <1% | 2,723 | $199K | |
| 0004A | <1% | 5,229 | $197K | |
| 86880 | <1% | 22,132 | $185K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,634 | $180K |
| 90378 | <1% | 141 | $178K | |
| 97803 | <1% | 5,517 | $176K | |
| 99201 | <1% | 1,882 | $176K | |
| 76642 | <1% | 1,921 | $176K | |
| 99347 | <1% | 1,046 | $173K | |
| 84703 | <1% | 54,406 | $173K | |
| 76641 | <1% | 1,280 | $164K | |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 1,290 | $163K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 95 | $163K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 715 | $160K |
| 86769 | <1% | 3,922 | $160K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,039 | $152K |
| 92579 | <1% | 2,690 | $152K | |
| 10060 | <1% | 880 | $150K | |
| 96127 | <1% | 43,841 | $149K | |
| 88142 | <1% | 6,410 | $147K | |
| 86235 | <1% | 1,920 | $146K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,006 | $142K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 42,587 | $137K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 348 | $136K |
| 87340 | <1% | 19,128 | $135K | |
| 59025 | Fetal non-stress test | <1% | 1,109 | $134K |
| 90746 | <1% | 2,304 | $128K | |
| 77062 | <1% | 825 | $128K | |
| 73610 | <1% | 5,886 | $125K | |
| 90697 | <1% | 3,730 | $125K | |
| 92582 | <1% | 1,322 | $125K | |
| 76536 | <1% | 1,119 | $124K | |
| 0072A | <1% | 3,309 | $124K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 908 | $124K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,049 | $123K |
| 92250 | <1% | 2,830 | $122K | |
| 58300 | <1% | 1,021 | $121K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,026 | $121K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 2,002 | $120K |
| D0140 | Limited oral evaluation - problem focused | <1% | 7,493 | $120K |
| 71271 | <1% | 459 | $119K | |
| 58301 | <1% | 820 | $118K | |
| 84702 | <1% | 24,743 | $117K | |
| 96161 | <1% | 15,453 | $116K | |
| 84439 | <1% | 16,055 | $116K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 709 | $115K |
| 0071A | <1% | 3,543 | $113K | |
| 99381 | <1% | 2,299 | $113K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,677 | $111K |
| 82728 | <1% | 10,283 | $111K | |
| 73564 | <1% | 3,910 | $110K | |
| 92567 | <1% | 4,209 | $109K | |
| 92557 | <1% | 2,571 | $107K | |
| 92558 | <1% | 4,452 | $106K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 3,740 | $105K |
| 11982 | <1% | 447 | $103K | |
| 86762 | <1% | 8,340 | $103K | |
| 0124A | <1% | 2,362 | $101K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,486 | $100K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,716 | $99K |
| 96040 | <1% | 1,229 | $98K | |
| 90670 | <1% | 8,526 | $98K | |
| 73630 | <1% | 4,818 | $98K | |
| 87507 | <1% | 814 | $97K | |
| 81243 | <1% | 2,179 | $97K | |
| 11721 | <1% | 819 | $96K | |
| 73110 | <1% | 4,080 | $96K | |
| 86003 | <1% | 2,433 | $96K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,406 | $96K |
| 19083 | <1% | 119 | $93K | |
| 93247 | <1% | 562 | $93K | |
| 86765 | <1% | 8,118 | $90K | |
| 83880 | <1% | 5,324 | $89K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,144 | $89K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14,827 | $89K |
| 11981 | <1% | 424 | $89K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,779 | $88K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 502 | $87K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 95 | $87K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 174 | $86K |
| 92550 | <1% | 3,241 | $84K | |
| 73130 | <1% | 4,370 | $83K | |
| 94726 | <1% | 1,141 | $82K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 729 | $82K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,573 | $81K |
| 86735 | <1% | 8,105 | $80K | |
| S9122 | Home health aide or certified nurse assistant, providing care in the home; per hour | <1% | 1,029 | $80K |
| 92083 | <1% | 1,389 | $79K | |
| 76820 | <1% | 1,840 | $79K | |
| 86787 | <1% | 8,116 | $79K | |
| 86706 | <1% | 10,099 | $78K | |
| 87486 | <1% | 3,910 | $77K | |
| 99404 | <1% | 248 | $76K | |
| 85610 | <1% | 28,128 | $76K | |
| 73030 | <1% | 3,745 | $75K | |
| 80076 | <1% | 9,226 | $75K | |
| H0049 | Alcohol and/or drug screening | <1% | 1,118 | $75K |
| 90480 | <1% | 2,047 | $74K | |
| 92015 | Determination of refractive state | <1% | 3,280 | $74K |
| 95816 | <1% | 182 | $71K | |
| 97165 | <1% | 660 | $69K | |
| 83020 | <1% | 5,878 | $69K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,116 | $68K |
| 93971 | <1% | 932 | $67K | |
| 72100 | <1% | 2,189 | $65K | |
| 83970 | <1% | 1,808 | $64K | |
| 87581 | <1% | 3,909 | $64K | |
| 11720 | <1% | 1,393 | $64K | |
| 94729 | <1% | 1,115 | $63K | |
| G0493 | Skilled services of a registered nurse (rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting) | <1% | 319 | $62K |
| 99383 | <1% | 966 | $61K | |
| 82607 | <1% | 5,544 | $61K | |
| 81001 | <1% | 46,944 | $61K | |
| 92551 | <1% | 10,772 | $60K | |
| 73140 | <1% | 2,170 | $59K | |
| 76000 | <1% | 459 | $59K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 830 | $58K |
| 90732 | <1% | 628 | $58K | |
| 58100 | <1% | 123 | $57K | |
| 74018 | <1% | 2,562 | $55K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 259 | $55K |
| 36430 | <1% | 382 | $54K | |
| 92133 | <1% | 1,404 | $54K | |
| 90734 | <1% | 2,273 | $54K | |
| 11900 | <1% | 427 | $53K | |
| 72131 | <1% | 491 | $53K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,303 | $53K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 40 | $52K |
| 83001 | <1% | 2,961 | $51K | |
| 87081 | <1% | 13,882 | $51K | |
| 73590 | <1% | 3,132 | $50K | |
| 91320 | <1% | 1,033 | $50K | |
| 95117 | <1% | 2,611 | $50K | |
| 83550 | <1% | 7,986 | $50K | |
| 73560 | <1% | 1,853 | $49K | |
| 84146 | <1% | 2,773 | $49K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,366 | $48K |
| 82951 | <1% | 4,293 | $48K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,053 | $48K |
| 97010 | <1% | 5,755 | $47K | |
| 90681 | <1% | 6,016 | $47K | |
| 94060 | <1% | 582 | $46K | |
| 20610 | <1% | 330 | $46K | |
| 83540 | <1% | 9,201 | $45K | |
| 96367 | <1% | 1,023 | $45K | |
| 59840 | <1% | 72 | $45K | |
| 90707 | <1% | 1,363 | $44K | |
| 69209 | <1% | 322 | $44K | |
| 82784 | <1% | 2,278 | $44K | |
| 85007 | <1% | 17,759 | $43K | |
| 83883 | <1% | 2,026 | $43K | |
| 82670 | <1% | 1,606 | $43K | |
| 82805 | <1% | 5,938 | $42K | |
| 82785 | <1% | 2,741 | $42K | |
| 76870 | <1% | 679 | $42K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 539 | $41K |
| D0330 | Panoramic radiographic image | <1% | 2,935 | $41K |
| 82948 | <1% | 30,739 | $41K | |
| 93308 | <1% | 438 | $40K | |
| 90723 | <1% | 6,004 | $40K | |
| 83516 | <1% | 2,921 | $39K | |
| 73700 | <1% | 221 | $39K | |
| 99051 | <1% | 3,183 | $39K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 203 | $39K |
| 99384 | <1% | 733 | $38K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,128 | $38K |
| 96415 | <1% | 148 | $38K | |
| 29125 | <1% | 290 | $37K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 40 | $37K |
| D1206 | Topical application of fluoride varnish | <1% | 5,924 | $36K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 667 | $36K |
| 77061 | <1% | 270 | $36K | |
| 97161 | <1% | 358 | $36K | |
| 90633 | <1% | 4,788 | $36K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 357 | $36K |
| 90656 | <1% | 2,978 | $35K | |
| 86704 | <1% | 4,395 | $35K | |
| 96523 | <1% | 143 | $35K | |
| 83002 | <1% | 2,041 | $35K | |
| 73502 | <1% | 1,287 | $34K | |
| S9129 | Occupational therapy, in the home, per diem | <1% | 495 | $33K |
| 94664 | <1% | 1,741 | $33K | |
| 84402 | <1% | 1,345 | $33K | |
| 85730 | <1% | 20,008 | $33K | |
| 97804 | <1% | 3,245 | $33K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 1,276 | $32K |
| 86140 | <1% | 9,794 | $32K | |
| 0081A | <1% | 704 | $31K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,409 | $31K |
| 88307 | <1% | 331 | $31K | |
| 84403 | <1% | 1,295 | $31K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,992 | $30K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 132 | $30K |
| 90620 | <1% | 1,834 | $30K | |
| 84153 | <1% | 2,082 | $29K | |
| 73090 | <1% | 2,170 | $29K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 9,736 | $29K |
| 57454 | <1% | 98 | $29K | |
| 76376 | <1% | 432 | $28K | |
| 82570 | <1% | 6,792 | $28K | |
| 99382 | <1% | 472 | $27K | |
| 83690 | <1% | 19,406 | $27K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 121 | $27K |
| 29580 | <1% | 205 | $26K | |
| 93246 | <1% | 557 | $26K | |
| 90716 | <1% | 1,097 | $26K | |
| 90647 | <1% | 3,959 | $25K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 51 | $25K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 73 | $25K |
| D1120 | Dental cleaning, child | <1% | 4,286 | $25K |
| 74019 | <1% | 1,027 | $25K | |
| 88112 | <1% | 328 | $25K | |
| 81003 | <1% | 14,830 | $25K | |
| 82043 | <1% | 5,334 | $25K | |
| 86160 | <1% | 1,576 | $25K | |
| 73080 | <1% | 1,388 | $24K | |
| 90710 | <1% | 2,931 | $24K | |
| 90648 | <1% | 2,955 | $24K | |
| 0082A | <1% | 529 | $24K | |
| 80320 | <1% | 11,192 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,565 | $23K |
| 59841 | <1% | 37 | $23K | |
| 83525 | <1% | 1,938 | $23K | |
| 84100 | <1% | 11,843 | $23K | |
| 73120 | <1% | 923 | $23K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 513 | $23K |
| 92650 | <1% | 698 | $23K | |
| 83735 | <1% | 18,216 | $22K | |
| 73070 | <1% | 1,387 | $22K | |
| 82627 | <1% | 1,033 | $22K | |
| 99173 | <1% | 8,648 | $21K | |
| 16020 | <1% | 108 | $21K | |
| 83498 | <1% | 774 | $21K | |
| 99188 | <1% | 2,371 | $20K | |
| 87517 | <1% | 472 | $20K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 54 | $20K |
| 77080 | <1% | 583 | $20K | |
| 76981 | <1% | 166 | $20K | |
| 72128 | <1% | 252 | $20K | |
| 76857 | <1% | 450 | $20K | |
| 92134 | <1% | 466 | $19K | |
| 81025 | <1% | 5,130 | $19K | |
| P9021 | Red blood cells, each unit | <1% | 109 | $19K |
| 84156 | <1% | 6,426 | $19K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 831 | $19K |
| 88304 | <1% | 764 | $19K | |
| 0154A | <1% | 441 | $18K | |
| 51701 | <1% | 80 | $18K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 24 | $18K |
| 92587 | <1% | 620 | $18K | |
| D0120 | Dental checkup, returning patient | <1% | 3,501 | $18K |
| 73562 | <1% | 895 | $18K | |
| 92002 | <1% | 231 | $18K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,694 | $18K |
| 86008 | <1% | 252 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 143 | $17K |
| 94010 | <1% | 356 | $17K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 25 | $17K |
| 84484 | <1% | 15,812 | $16K | |
| 87536 | <1% | 176 | $16K | |
| 99385 | <1% | 209 | $16K | |
| 20611 | <1% | 90 | $16K | |
| 85651 | <1% | 6,041 | $16K | |
| 87186 | <1% | 4,384 | $16K | |
| 82105 | <1% | 1,211 | $16K | |
| 82550 | <1% | 7,066 | $16K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 12 | $16K |
| 73620 | <1% | 582 | $16K | |
| D9310 | <1% | 643 | $16K | |
| 99402 | <1% | 198 | $15K | |
| H0001 | Alcohol and/or drug assessment | <1% | 72 | $15K |
| 73552 | <1% | 983 | $15K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 3,881 | $15K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 26 | $15K |
| 86592 | <1% | 3,582 | $15K | |
| 90700 | <1% | 1,968 | $14K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14,424 | $14K |
| 85240 | <1% | 1,001 | $14K | |
| 58340 | <1% | 37 | $14K | |
| 93017 | <1% | 231 | $14K | |
| 84480 | <1% | 1,310 | $14K | |
| 85060 | <1% | 799 | $14K | |
| 83615 | <1% | 3,304 | $14K | |
| 88141 | <1% | 632 | $13K | |
| D1110 | Prophylaxis - adult | <1% | 1,104 | $13K |
| 72170 | <1% | 1,628 | $13K | |
| 86376 | <1% | 929 | $13K | |
| S0190 | Mifepristone, oral, 200 mg | <1% | 229 | $13K |
| 82465 | <1% | 3,711 | $13K | |
| 87522 | Neg quan hep c or qual rna | <1% | 307 | $12K |
| 86258 | <1% | 674 | $12K | |
| 82248 | <1% | 2,862 | $12K | |
| 85045 | <1% | 3,967 | $12K | |
| 73060 | <1% | 908 | $12K | |
| 87184 | <1% | 3,823 | $11K | |
| 97162 | <1% | 111 | $11K | |
| 86038 | <1% | 1,216 | $11K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 26 | $11K |
| 82274 | <1% | 1,025 | $11K | |
| 84550 | <1% | 2,907 | $11K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,380 | $11K |
| 82947 | <1% | 2,930 | $10K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 4,016 | $10K |
| 70491 | <1% | 55 | $10K | |
| 87338 | <1% | 906 | $10K | |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 87 | $10K |
| 85306 | <1% | 807 | $10K | |
| 82677 | <1% | 488 | $10K | |
| 0074A | <1% | 247 | $10K | |
| 57460 | <1% | 13 | $10K | |
| 85303 | <1% | 855 | $10K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 59 | $10K |
| 86255 | <1% | 1,007 | $10K | |
| 31575 | <1% | 25 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,035 | $10K |
| 0003A | <1% | 232 | $9K | |
| 52000 | <1% | 13 | $9K | |
| 85307 | <1% | 714 | $9K | |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 26 | $9K |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 395 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,061 | $9K |
| 90837 | Psychotherapy session, about an hour | <1% | 48 | $9K |
| 73600 | <1% | 482 | $9K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,083 | $9K |
| 12013 | <1% | 25 | $9K | |
| 82746 | <1% | 968 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18,524 | $9K |
| 73521 | <1% | 303 | $9K | |
| 99386 | <1% | 60 | $8K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 13 | $8K |
| 90696 | <1% | 1,257 | $8K | |
| 76775 | <1% | 614 | $8K | |
| 92555 | <1% | 180 | $8K | |
| 96167 | <1% | 204 | $8K | |
| 82977 | <1% | 1,238 | $8K | |
| 96417 | <1% | 95 | $8K | |
| 76998 | <1% | 70 | $8K | |
| V2020 | Frames, purchases | <1% | 109 | $8K |
| 84445 | <1% | 152 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 324 | $7K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,898 | $7K |
| 86593 | <1% | 2,176 | $7K | |
| 74178 | <1% | 25 | $7K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 28 | $7K |
| 90678 | <1% | 140 | $7K | |
| 86708 | <1% | 668 | $7K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 26 | $7K |
| 84466 | <1% | 567 | $7K | |
| 85379 | <1% | 2,304 | $7K | |
| 87070 | <1% | 2,030 | $7K | |
| 93923 | <1% | 52 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,808 | $6K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 370 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,373 | $6K |
| 96112 | <1% | 112 | $6K | |
| 90744 | <1% | 855 | $6K | |
| 17110 | <1% | 46 | $6K | |
| 82157 | <1% | 209 | $6K | |
| 96380 | <1% | 571 | $6K | |
| 85018 | <1% | 2,741 | $6K | |
| 84704 | <1% | 485 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,446 | $6K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 901 | $6K |
| 73000 | <1% | 264 | $6K | |
| 96376 | <1% | 2,723 | $6K | |
| 92227 | <1% | 195 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,251 | $6K |
| 96160 | <1% | 463 | $6K | |
| 86336 | <1% | 487 | $6K | |
| D0272 | Bitewings - two radiographic images | <1% | 2,652 | $6K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 4,203 | $6K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,206 | $5K |
| 97116 | <1% | 163 | $5K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,806 | $5K |
| 93886 | <1% | 12 | $5K | |
| 70487 | <1% | 16 | $5K | |
| 93226 | <1% | 76 | $5K | |
| 0083A | <1% | 108 | $5K | |
| 98960 | <1% | 263 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,976 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 489 | $5K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 294 | $5K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 105 | $5K |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 46 | $5K |
| 85300 | <1% | 537 | $5K | |
| 87529 | <1% | 190 | $5K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,511 | $5K |
| 84460 | <1% | 899 | $5K | |
| 86682 | <1% | 443 | $5K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 72 | $5K |
| 80165 | <1% | 896 | $5K | |
| 71101 | <1% | 247 | $4K | |
| D1351 | Sealant - per tooth | <1% | 1,104 | $4K |
| 74740 | <1% | 12 | $4K | |
| 86334 | <1% | 218 | $4K | |
| 90662 | <1% | 311 | $4K | |
| 86696 | <1% | 269 | $4K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 2,265 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,269 | $4K |
| 90714 | <1% | 497 | $4K | |
| D0367 | <1% | 28 | $4K | |
| 0011A | <1% | 248 | $4K | |
| 86705 | <1% | 560 | $4K | |
| 29130 | <1% | 27 | $4K | |
| 86430 | <1% | 756 | $4K | |
| 95886 | <1% | 39 | $4K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 86 | $4K |
| 59425 | <1% | 59 | $4K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 12 | $4K |
| 90671 | <1% | 554 | $4K | |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 31 | $4K |
| G0495 | Skilled services of a registered nurse (rn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes | <1% | 22 | $3K |
| 72190 | <1% | 109 | $3K | |
| D9990 | <1% | 785 | $3K | |
| 73100 | <1% | 177 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,866 | $3K |
| D0274 | Bitewings - four radiographic images | <1% | 643 | $3K |
| 84165 | <1% | 451 | $3K | |
| 81514 | <1% | 16 | $3K | |
| 73660 | <1% | 169 | $3K | |
| 80329 | <1% | 121 | $3K | |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | <1% | 19 | $3K |
| 86923 | <1% | 107 | $3K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 5,194 | $3K |
| 69210 | <1% | 36 | $3K | |
| 81257 | <1% | 49 | $3K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 37 | $3K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 20 | $3K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 424 | $3K |
| 20550 | <1% | 14 | $3K | |
| 90653 | <1% | 174 | $3K | |
| 99409 | <1% | 91 | $3K | |
| 82378 | <1% | 173 | $3K | |
| 76885 | <1% | 24 | $3K | |
| 72070 | <1% | 91 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,045 | $3K |
| 88300 | <1% | 317 | $3K | |
| 82952 | <1% | 1,063 | $2K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 266 | $2K |
| 86695 | <1% | 200 | $2K | |
| 86580 | <1% | 311 | $2K | |
| 76814 | <1% | 130 | $2K | |
| 91318 | <1% | 356 | $2K | |
| 82397 | <1% | 616 | $2K | |
| 90694 | <1% | 150 | $2K | |
| 97168 | <1% | 25 | $2K | |
| D0191 | <1% | 2,579 | $2K | |
| 95885 | <1% | 30 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 13 | $2K |
| 81002 | <1% | 497 | $2K | |
| 99412 | <1% | 40 | $2K | |
| 87077 | <1% | 982 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,651 | $2K |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | <1% | 12 | $2K |
| 74174 | <1% | 12 | $2K | |
| 82150 | <1% | 532 | $2K | |
| 84305 | <1% | 96 | $2K | |
| 86709 | <1% | 212 | $2K | |
| 83520 | <1% | 96 | $2K | |
| 91319 | <1% | 325 | $2K | |
| 95251 | <1% | 30 | $2K | |
| D9222 | <1% | 41 | $2K | |
| 82533 | <1% | 103 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,428 | $2K |
| D0603 | <1% | 2,199 | $2K | |
| 74022 | <1% | 108 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 59 | $2K |
| 87040 | <1% | 1,164 | $2K | |
| 84681 | <1% | 84 | $2K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 24 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,391 | $2K |
| 94761 | <1% | 371 | $2K | |
| 90674 | <1% | 77 | $2K | |
| 74240 | <1% | 13 | $2K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 228 | $2K |
| 83605 | <1% | 799 | $2K | |
| 77072 | <1% | 57 | $2K | |
| 87593 | <1% | 36 | $1K | |
| 87205 | <1% | 860 | $1K | |
| 86146 | <1% | 85 | $1K | |
| 87631 | <1% | 25 | $1K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 248 | $1K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 681 | $1K |
| 92586 | <1% | 12 | $1K | |
| 82803 | <1% | 523 | $1K | |
| 92610 | <1% | 12 | $1K | |
| D0270 | <1% | 190 | $1K | |
| 86618 | <1% | 79 | $1K | |
| 69200 | <1% | 17 | $1K | |
| 92060 | <1% | 15 | $1K | |
| 82652 | <1% | 44 | $1K | |
| 0012A | <1% | 64 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,006 | $1K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 4,454 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,728 | $1K |
| 99411 | <1% | 263 | $991.72 | |
| 86381 | <1% | 41 | $982.96 | |
| 87177 | <1% | 108 | $971.14 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 10,994 | $949.26 |
| 82787 | <1% | 157 | $941.09 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 453 | $933.95 |
| 80050 | General health panel | <1% | 468 | $924.78 |
| 86225 | <1% | 114 | $914.90 | |
| 82272 | <1% | 257 | $913.32 | |
| D1354 | <1% | 478 | $909.50 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,046 | $902.44 |
| 93325 | <1% | 30 | $897.37 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,845 | $882.93 |
| 90381 | <1% | 155 | $858.53 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 384 | $858.26 |
| 85613 | <1% | 111 | $858.00 | |
| P9010 | Blood (whole), for transfusion, per unit | <1% | 15 | $849.20 |
| 72040 | <1% | 27 | $838.66 | |
| 83521 | <1% | 54 | $785.10 | |
| S0580 | Polycarbonate lens (list this code in addition to the basic code for the lens) | <1% | 35 | $755.48 |
| 83010 | <1% | 68 | $747.91 | |
| 82166 | <1% | 28 | $726.79 | |
| 86231 | <1% | 69 | $717.03 | |
| 72052 | <1% | 14 | $711.91 | |
| 86141 | <1% | 188 | $699.34 | |
| 82247 | <1% | 201 | $682.01 | |
| 87075 | <1% | 259 | $667.08 | |
| 87045 | <1% | 201 | $661.12 | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 702 | $657.50 |
| 82010 | <1% | 774 | $654.89 | |
| 99152 | <1% | 234 | $636.62 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 621 | $636.15 |
| 86320 | <1% | 27 | $634.60 | |
| 90688 | <1% | 54 | $617.69 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 8,003 | $589.64 |
| 80178 | <1% | 233 | $588.49 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 380 | $572.62 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 369 | $517.69 |
| 86777 | <1% | 30 | $503.18 | |
| 0031A | <1% | 17 | $502.87 | |
| 82088 | <1% | 12 | $495.49 | |
| J3230 | Injection, chlorpromazine hcl, up to 50 mg | <1% | 88 | $485.82 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,999 | $481.89 |
| 94760 | <1% | 155 | $462.05 | |
| 90474 | <1% | 100 | $450.72 | |
| 82390 | <1% | 45 | $445.46 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 36 | $437.64 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,722 | $413.05 |
| 99406 | <1% | 270 | $378.62 | |
| 90380 | <1% | 66 | $378.14 | |
| 90713 | <1% | 31 | $357.81 | |
| 97124 | <1% | 13 | $352.40 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 316 | $344.33 |
| 76514 | <1% | 14 | $339.76 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 91 | $336.70 |
| 3078F | <1% | 83,565 | $336.15 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,924 | $266.82 |
| 84144 | <1% | 14 | $260.77 | |
| D0171 | <1% | 34 | $249.24 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 322 | $244.18 |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 12 | $240.35 |
| 85244 | <1% | 12 | $232.26 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 126 | $232.20 |
| 85384 | <1% | 78 | $231.45 | |
| 82103 | <1% | 14 | $199.13 | |
| 70360 | <1% | 13 | $198.66 | |
| 87210 | <1% | 45 | $198.50 | |
| 0173A | <1% | 27 | $197.48 | |
| 96368 | <1% | 32 | $193.06 | |
| 80069 | <1% | 16 | $168.73 | |
| 92568 | <1% | 14 | $159.06 | |
| 87046 | <1% | 12 | $156.84 | |
| D0350 | <1% | 13 | $155.18 | |
| 0073A | <1% | 30 | $151.20 | |
| 80349 | <1% | 42 | $147.25 | |
| J1815 | Injection, insulin, per 5 units | <1% | 507 | $136.33 |
| 1159F | <1% | 7,415 | $124.23 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 103 | $123.50 |
| 90685 | <1% | 262 | $117.94 | |
| 86665 | <1% | 12 | $116.10 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 143 | $102.90 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 120 | $102.20 |
| 84478 | <1% | 13 | $95.81 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 64 | $87.23 |
| OP250 | <1% | 22 | $80.51 | |
| 87088 | <1% | 26 | $71.06 | |
| 84155 | <1% | 26 | $66.62 | |
| 86664 | <1% | 12 | $64.22 | |
| 84512 | <1% | 165 | $62.35 | |
| 87420 | <1% | 32 | $55.38 | |
| 86663 | <1% | 12 | $55.10 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 96 | $50.14 |
| 84436 | <1% | 24 | $47.33 | |
| 87275 | <1% | 118 | $42.16 | |
| 87276 | <1% | 118 | $42.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 296 | $41.79 |
| 3075F | <1% | 19,944 | $41.76 | |
| 80156 | <1% | 14 | $40.73 | |
| 85660 | <1% | 12 | $39.75 | |
| G0008 | Administration of influenza virus vaccine | <1% | 316 | $32.35 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 114 | $30.95 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 13 | $27.79 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 27 | $20.89 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 13 | $15.10 |
| 3074F | <1% | 88,978 | $14.58 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 39 | $9.40 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 184 | $5.83 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 13 | $4.59 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 19 | $2.53 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 32 | $1.85 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 21 | $0.86 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 41 | $0.10 |
| 0502F | <1% | 573 | $0.06 | |
| 3079F | <1% | 32,781 | $0.01 | |
| 3080F | 0% | 5,373 | $0.00 | |
| D0602 | 0% | 93 | $0.00 | |
| 99429 | 0% | 1,214 | $0.00 | |
| 1220F | 0% | 1,008 | $0.00 | |
| 3044F | 0% | 381 | $0.00 | |
| D0240 | 0% | 18 | $0.00 | |
| 76604 | 0% | 12 | $0.00 | |
| G0436 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | 0% | 406 | $0.00 |
| 1CHK1 | 0% | 63 | $0.00 | |
| 87110 | 0% | 12 | $0.00 | |
| 3072F | 0% | 16 | $0.00 | |
| 3077F | 0% | 13,353 | $0.00 | |
| 1160F | 0% | 5,805 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 404 | $0.00 |
| 99080 | 0% | 10,097 | $0.00 | |
| 1AA11 | 0% | 56 | $0.00 | |
| 99499 | 0% | 4,355 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 54 | $0.00 |
| G0445 | High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes | 0% | 347 | $0.00 |
| 82375 | 0% | 13 | $0.00 | |
| 77055 | 0% | 14 | $0.00 | |
| 2022F | 0% | 16 | $0.00 | |
| 92202 | 0% | 14 | $0.00 | |
| D0190 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.